New Phase 3 data from Gilead Sciences and Merck support what could become the first complete once-weekly oral treatment for HIV. If approved, the investigational combination of lenacapavir and islatravir could offer people living with HIV a new option that reduces the burden of daily medication while maintaining viral suppression.
Advances like this reflect how innovation continues to reshape HIV care—not only by improving clinical outcomes but also by making treatment more convenient and supporting long-term adherence.
At The Bandish Group, we recognize that breakthroughs like these are made possible by the scientists, clinicians, regulatory professionals, and commercial leaders driving innovation across the life sciences industry. As the pace of innovation accelerates, so does the need for exceptional talent.
Click here to read this article.
